FR3128872B1 - Nouvelles combinaisons synergiques a base de fenm - Google Patents

Nouvelles combinaisons synergiques a base de fenm Download PDF

Info

Publication number
FR3128872B1
FR3128872B1 FR2111841A FR2111841A FR3128872B1 FR 3128872 B1 FR3128872 B1 FR 3128872B1 FR 2111841 A FR2111841 A FR 2111841A FR 2111841 A FR2111841 A FR 2111841A FR 3128872 B1 FR3128872 B1 FR 3128872B1
Authority
FR
France
Prior art keywords
disease
fenm
dementia
combinations based
synergistic combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2111841A
Other languages
English (en)
French (fr)
Other versions
FR3128872A1 (fr
Inventor
Gilles Rubinstenn
Tangui Maurice
Aline Freyssin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Ecole Pratique des Hautes Etudes SAS
Rest Therapeutics SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Ecole Pratique des Hautes Etudes SAS
Rest Therapeutics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Montpellier, Ecole Pratique des Hautes Etudes SAS, Rest Therapeutics SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR2111841A priority Critical patent/FR3128872B1/fr
Priority to JP2024549574A priority patent/JP2025500088A/ja
Priority to US18/708,355 priority patent/US20250000818A1/en
Priority to EP22817139.3A priority patent/EP4429648A1/fr
Priority to PCT/EP2022/081184 priority patent/WO2023079187A1/fr
Publication of FR3128872A1 publication Critical patent/FR3128872A1/fr
Application granted granted Critical
Publication of FR3128872B1 publication Critical patent/FR3128872B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR2111841A 2021-11-08 2021-11-08 Nouvelles combinaisons synergiques a base de fenm Active FR3128872B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR2111841A FR3128872B1 (fr) 2021-11-08 2021-11-08 Nouvelles combinaisons synergiques a base de fenm
JP2024549574A JP2025500088A (ja) 2021-11-08 2022-11-08 Ｆｅｎｍ及びアセチルコリンエステラーゼ阻害剤をベースとする新規相乗的組合せ
US18/708,355 US20250000818A1 (en) 2021-11-08 2022-11-08 New synergistic combinations based on fenm and an acetylcholinesterase inhibitor
EP22817139.3A EP4429648A1 (fr) 2021-11-08 2022-11-08 Nouvelles combinaisons synergiques a base de fenm et un inhibiteur de l'acétylcholinestérase
PCT/EP2022/081184 WO2023079187A1 (fr) 2021-11-08 2022-11-08 Nouvelles combinaisons synergiques a base de fenm et un inhibiteur de l'acétylcholinestérase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2111841A FR3128872B1 (fr) 2021-11-08 2021-11-08 Nouvelles combinaisons synergiques a base de fenm
FR2111841 2021-11-08

Publications (2)

Publication Number Publication Date
FR3128872A1 FR3128872A1 (fr) 2023-05-12
FR3128872B1 true FR3128872B1 (fr) 2024-09-13

Family

ID=80595290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2111841A Active FR3128872B1 (fr) 2021-11-08 2021-11-08 Nouvelles combinaisons synergiques a base de fenm

Country Status (5)

Country Link
US (1) US20250000818A1 (https=)
EP (1) EP4429648A1 (https=)
JP (1) JP2025500088A (https=)
FR (1) FR3128872B1 (https=)
WO (1) WO2023079187A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2012E (fr) 1903-02-06 1903-11-24 Otto Massenez Procédé pour transformer en acier des fontes contenant des quantités considérables de chrome
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
FR3006193B1 (fr) 2013-05-29 2015-06-19 Holis Technologies Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda)
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS

Also Published As

Publication number Publication date
EP4429648A1 (fr) 2024-09-18
FR3128872A1 (fr) 2023-05-12
WO2023079187A1 (fr) 2023-05-11
JP2025500088A (ja) 2025-01-08
US20250000818A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
CA3156499A1 (en) CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
MA54386B1 (fr) Modulateurs de trex1
MA30806B1 (fr) Phosphoindoles enantiomeriquement purs utilisables en tant qu'inhibiteurs du vih
MA52488B1 (fr) Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
EP1841426A4 (en) ACTIVE TERTIARY CARBINAMINES WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER DISEASE AS INHIBITORS OF BETA-SECRETASE
MA43756B1 (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
TN2019000126A1 (fr) Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
DE60121922D1 (de) Verfahren und zusammenstellung für einen suplantataufbau
MA31198B1 (fr) Nouvelle forme dosifiee
BR112022022405A2 (pt) Composições para tratamento bucal compreendendo ácido dicarboxílico
MA46611A (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
EP4460524A4 (en) Compositions and methods for treatment of thyroid eye disease
MX2021002012A (es) Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico.
EP3911329A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC LIVER DISEASES
FR3128872B1 (fr) Nouvelles combinaisons synergiques a base de fenm
WO2018049003A8 (en) ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND THEIR METHODS OF USE
FR3108504B1 (fr) Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement d’altérations de la fonction respiratoire lors d’une infection virale
MA30662B1 (fr) Derives de phenyl-prenyl-ether pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux
FR3093427B1 (fr) Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
FR3149773B1 (fr) Nouvelles combinaisons synergiques a base de fenm
CA3156457A1 (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20230512

PLFP Fee payment

Year of fee payment: 3

CA Change of address

Effective date: 20231214

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5